Cardiovascular disease remains the leading cause of death in patients with diabetes.
Cardiovascular disease in diabetes is multifactorial, and control of the cardiovascular risk …

Key Clinical Points Glucose-Lowering Drugs to Reduce Cardiovascular Risk in Type 2
Diabetes The attainment of glycemic targets and comprehensive reduction in risk factors for …

Patients with type 2 diabetes (T2DM) have a significantly higher risk of developing
cardiovascular disease (CVD)—namely myocardial infarction, heart failure, and stroke …

Cardiovascular disease remains the principal cause of death and disability among patients
with diabetes mellitus. Diabetes mellitus exacerbates mechanisms underlying …

Cardiovascular disease is a leading cause of morbidity and mortality in individuals with type
2 diabetes mellitus. These high-risk patients benefit from aggressive risk factor …

Background The value of glycemic control and preexisting cardiovascular disease in
determining the risk of major cardiovascular events (MACE) in type 2 diabetes mellitus is …

Type 2 diabetes mellitus (T2D) is a major risk factor for cardiovascular disease (CVD), the
most common cause of death in T2D. Despite improved risk factor control, however, adults …

Type 2 diabetes mellitus is a major risk factor for developing cardiovascular disease, and
many patients with diabetes have prevalent cardiovascular complications. Recent …

Responding to concerns about the potential for increased risk of adverse cardiovascular
outcomes, specifically myocardial infarction, associated with certain glucose-lowering …

Background In our 2015 systematic review and meta-analysis of cardiovascular outcome
trials for glucose-lowering drugs or strategies in people with or at risk of type 2 diabetes, we …